Inventiva (IVA) Cash from Investing Activities (2019 - 2025)
Inventiva (IVA) posted quarterly Cash from Investing Activities of -$28.1 million for Q2 2025, down 10166.56% quarter-over-quarter from -$273426.3 in Q4 2022.
Analysis
Inventiva (IVA) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Inventiva's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$28.1 million for Q2 2025.
- In Q2 2025, Cash from Investing Activities changed N/A year-over-year to -$28.1 million; the TTM figure through Jun 2025 stood at -$23.2 million (changed N/A YoY), while the FY2025 annual figure was -$155.1 million, down 1759.21% from the prior year.
- Cash from Investing Activities for Q2 2025 stood at -$28.1 million, down from -$273426.3 in the prior quarter.
- The five-year high for Cash from Investing Activities was $7.7 million in Q1 2021, with the low at -$28.1 million in Q2 2025.
- The 3-year median for Cash from Investing Activities is -$276534.1 (2022), against an average of -$2.9 million.
- The sharpest annual moves came in 2021 and 2022: Cash from Investing Activities surged 553.88% in 2021, then slumped 105.04% in 2022.
- Inventiva's Cash from Investing Activities stood at $5.4 million in 2021, then plunged by 105.04% to -$273426.3 in 2022, then tumbled by 10166.56% to -$28.1 million in 2025.
- Business Quant data shows IVA's Cash from Investing Activities at -$28.1 million in Q2 2025, -$273426.3 in Q4 2022, and -$279641.8 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -28.07 Mn |
| Dec 31, 2022 | -273,426.29 |
| Sep 22, 2022 | -279,641.81 |
| Dec 31, 2021 | 5.42 Mn |
| Jun 30, 2021 | -1.97 Mn |
| Mar 31, 2021 | 7.69 Mn |
| Dec 31, 2020 | -1.19 Mn |
| Dec 31, 2019 | -928,678.76 |